JP2022509724A - 組み合わせ療法 - Google Patents
組み合わせ療法 Download PDFInfo
- Publication number
- JP2022509724A JP2022509724A JP2021513314A JP2021513314A JP2022509724A JP 2022509724 A JP2022509724 A JP 2022509724A JP 2021513314 A JP2021513314 A JP 2021513314A JP 2021513314 A JP2021513314 A JP 2021513314A JP 2022509724 A JP2022509724 A JP 2022509724A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- kras
- formula
- alkyl
- shp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 **(Cc(c(C1)n2)c(N3CCN(*)CC3)nc2O*)CN1I* Chemical compound **(Cc(c(C1)n2)c(N3CCN(*)CC3)nc2O*)CN1I* 0.000 description 2
- WPJCQLIABOVULI-UHFFFAOYSA-N C=CC(N(CC1)CCN1c1c(CCN(C2)c3cc(O)cc4c3cccc4)c2nc(NC(CC2)CCN2C2CC2)n1)=O Chemical compound C=CC(N(CC1)CCN1c1c(CCN(C2)c3cc(O)cc4c3cccc4)c2nc(NC(CC2)CCN2C2CC2)n1)=O WPJCQLIABOVULI-UHFFFAOYSA-N 0.000 description 2
- WXOSKZHOCYRUOA-UHFFFAOYSA-N C=CC(N(CC1)CCN1c1nc(OCCCN2CC(C3)C3C2)nc(C2)c1CCN2c1cc(O)cc2c1cccc2)=O Chemical compound C=CC(N(CC1)CCN1c1nc(OCCCN2CC(C3)C3C2)nc(C2)c1CCN2c1cc(O)cc2c1cccc2)=O WXOSKZHOCYRUOA-UHFFFAOYSA-N 0.000 description 2
- BOYBAZKNDIQEJS-HSZRJFAPSA-N C=CC(N(CC1)CCN1c1nc(OCCN(CCC2)C[C@@H]2F)nc(C2)c1CCN2c1cc(O)cc2ccccc12)=O Chemical compound C=CC(N(CC1)CCN1c1nc(OCCN(CCC2)C[C@@H]2F)nc(C2)c1CCN2c1cc(O)cc2ccccc12)=O BOYBAZKNDIQEJS-HSZRJFAPSA-N 0.000 description 2
- WUUYOPLSMFNPRF-ANYOKISRSA-N CN1[C@H](COc2nc(CN(CC3)c4cnccc4C(F)(F)F)c3c(N(CC3)CC(CC#N)N3C(C=C)=O)n2)CCC1 Chemical compound CN1[C@H](COc2nc(CN(CC3)c4cnccc4C(F)(F)F)c3c(N(CC3)CC(CC#N)N3C(C=C)=O)n2)CCC1 WUUYOPLSMFNPRF-ANYOKISRSA-N 0.000 description 2
- YXSCQRLUQFPPOJ-LBAQZLPGSA-N CN1[C@H](COc2nc(N(CC3)CC(CC#N)N3C(C=C)=O)c(CCN(C3)c4ccccc4C(F)(F)F)c3n2)CCC1 Chemical compound CN1[C@H](COc2nc(N(CC3)CC(CC#N)N3C(C=C)=O)c(CCN(C3)c4ccccc4C(F)(F)F)c3n2)CCC1 YXSCQRLUQFPPOJ-LBAQZLPGSA-N 0.000 description 2
- YSXBTZRNCSQYSX-UHFFFAOYSA-N Cc1ccc2[nH]ccc2c1N1Cc2nc(OCCCN3CCOCC3)nc(N(CC3)CCN3C(C=C)=O)c2CC1 Chemical compound Cc1ccc2[nH]ccc2c1N1Cc2nc(OCCCN3CCOCC3)nc(N(CC3)CCN3C(C=C)=O)c2CC1 YSXBTZRNCSQYSX-UHFFFAOYSA-N 0.000 description 2
- QYDRRJBZNLESHH-HSNKIBKKSA-N C/C=C(\c1c(C)cccc1C)/N1Cc2nc(OC[C@@H](C3)N(C)C[C@@H]3OC)nc(N(CC3)C[C@H](CC#N)N3C3(C(F)=C)OC3)c2CC1 Chemical compound C/C=C(\c1c(C)cccc1C)/N1Cc2nc(OC[C@@H](C3)N(C)C[C@@H]3OC)nc(N(CC3)C[C@H](CC#N)N3C3(C(F)=C)OC3)c2CC1 QYDRRJBZNLESHH-HSNKIBKKSA-N 0.000 description 1
- SEUJJFVZFDHBLR-QBHOUYDASA-N C=C(C(N(CC1)[C@@H](CC#N)CN1c1c(CCN(C2)c3cccc4c3c(Cl)ccc4)c2nc(OCC(CC2)N2C2CCCC2)n1)=O)F Chemical compound C=C(C(N(CC1)[C@@H](CC#N)CN1c1c(CCN(C2)c3cccc4c3c(Cl)ccc4)c2nc(OCC(CC2)N2C2CCCC2)n1)=O)F SEUJJFVZFDHBLR-QBHOUYDASA-N 0.000 description 1
- HBLZLXQLPIHQBA-SFHVURJKSA-N C=C(C(N(CC1)[C@@H](CC#N)CN1c1n[nH]c(C2)c1CCN2c1c2c(Cl)cccc2ccc1)=O)F Chemical compound C=C(C(N(CC1)[C@@H](CC#N)CN1c1n[nH]c(C2)c1CCN2c1c2c(Cl)cccc2ccc1)=O)F HBLZLXQLPIHQBA-SFHVURJKSA-N 0.000 description 1
- OXCJEOQZAFLZFZ-UHFFFAOYSA-N C=CC(N(CC1)CCN1c1c(CCN(C2)c3c(cc(cc4)O)c4ccc3)c2ncn1)=O Chemical compound C=CC(N(CC1)CCN1c1c(CCN(C2)c3c(cc(cc4)O)c4ccc3)c2ncn1)=O OXCJEOQZAFLZFZ-UHFFFAOYSA-N 0.000 description 1
- KJGJYCRTUNZPRN-UHFFFAOYSA-N C=CC(N(CC1)CCN1c1c(CCN(C2)c3cccc4ccccc34)c2ncn1)=O Chemical compound C=CC(N(CC1)CCN1c1c(CCN(C2)c3cccc4ccccc34)c2ncn1)=O KJGJYCRTUNZPRN-UHFFFAOYSA-N 0.000 description 1
- SFWHFRMOVMVFIW-UHFFFAOYSA-N C=CC(N(CC1)CCN1c1nc(COCCCN2CCOCC2)nc(C2)c1CCN2c1cc(O)cc2cccnc12)=O Chemical compound C=CC(N(CC1)CCN1c1nc(COCCCN2CCOCC2)nc(C2)c1CCN2c1cc(O)cc2cccnc12)=O SFWHFRMOVMVFIW-UHFFFAOYSA-N 0.000 description 1
- DFOQXOCAOPDSAS-WMPKNSHKSA-N C=CC(N(CC1)CCN1c1nc(OCCCN(C[C@H]2F)C[C@@H]2F)nc(C2)c1CCN2c1cc(O)cc2ccccc12)=O Chemical compound C=CC(N(CC1)CCN1c1nc(OCCCN(C[C@H]2F)C[C@@H]2F)nc(C2)c1CCN2c1cc(O)cc2ccccc12)=O DFOQXOCAOPDSAS-WMPKNSHKSA-N 0.000 description 1
- GEBSVSDTSVCYCM-UHFFFAOYSA-N C=CC(N(CC1)CCN1c1nc(OCCCN2CCOCC2)nc(C2)c1CCN2c1cc(O)cc2cccnc12)=O Chemical compound C=CC(N(CC1)CCN1c1nc(OCCCN2CCOCC2)nc(C2)c1CCN2c1cc(O)cc2cccnc12)=O GEBSVSDTSVCYCM-UHFFFAOYSA-N 0.000 description 1
- RCJYJAPVGZQYPT-PPVAYSNCSA-N CC1(COc2nc(CN(CC3)c4cccc5cccc(Cl)c45)c3c(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)n2)N(C)CCC1 Chemical compound CC1(COc2nc(CN(CC3)c4cccc5cccc(Cl)c45)c3c(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)n2)N(C)CCC1 RCJYJAPVGZQYPT-PPVAYSNCSA-N 0.000 description 1
- HBBFXRZSZARDMI-LDNAWNGRSA-N CC12C(Cl)=CC=CC1C=CC=C2N(CC1)Cc2c1c(N(CC1)C[C@H](CC#N)N1C(/C=C/CO)=O)nc(OC[C@H]1N(C)CCC1)n2 Chemical compound CC12C(Cl)=CC=CC1C=CC=C2N(CC1)Cc2c1c(N(CC1)C[C@H](CC#N)N1C(/C=C/CO)=O)nc(OC[C@H]1N(C)CCC1)n2 HBBFXRZSZARDMI-LDNAWNGRSA-N 0.000 description 1
- SQSPHLBZAOINIK-NBZVVLFJSA-N CCC1(COc2nc(CN(CC3)c4c5c(Cl)cccc5ccc4)c3c(N(CC3)C[C@H](CC#N)N3C(/C=C/CF)=O)n2)N(C)CCC1 Chemical compound CCC1(COc2nc(CN(CC3)c4c5c(Cl)cccc5ccc4)c3c(N(CC3)C[C@H](CC#N)N3C(/C=C/CF)=O)n2)N(C)CCC1 SQSPHLBZAOINIK-NBZVVLFJSA-N 0.000 description 1
- ACHOQXUYKLAAPU-UHFFFAOYSA-N CCN(Cc1c(C)c(N(CC2)CCN2C(C=C)=O)nc(OCCCN2CCOCC2)n1)c1c(C)c(C)cc(O)c1 Chemical compound CCN(Cc1c(C)c(N(CC2)CCN2C(C=C)=O)nc(OCCCN2CCOCC2)n1)c1c(C)c(C)cc(O)c1 ACHOQXUYKLAAPU-UHFFFAOYSA-N 0.000 description 1
- XUBGTZPGSBYUOK-JEVDYFGZSA-N CN(C)C/C=C/C(N(CC1)CCN1c1nc(OC[C@H]2N(C)CCC2)nc(C2)c1CCN2c1cc(O)cc2ccccc12)=O Chemical compound CN(C)C/C=C/C(N(CC1)CCN1c1nc(OC[C@H]2N(C)CCC2)nc(C2)c1CCN2c1cc(O)cc2ccccc12)=O XUBGTZPGSBYUOK-JEVDYFGZSA-N 0.000 description 1
- WALXKNUIXQWICD-LBAQZLPGSA-N CN1[C@H](COc2nc(CN(CC3)c(cccc4)c4OC(F)(F)F)c3c(N(CC3)CC(CC#N)N3C(C=C)=O)n2)CCC1 Chemical compound CN1[C@H](COc2nc(CN(CC3)c(cccc4)c4OC(F)(F)F)c3c(N(CC3)CC(CC#N)N3C(C=C)=O)n2)CCC1 WALXKNUIXQWICD-LBAQZLPGSA-N 0.000 description 1
- XMYPBYHRAIBTEZ-QHCPKHFHSA-N CN1[C@H](COc2nc(CN(CC3)c4c(cccc5)c5ccc4)c3c(N(CC3)CCN3C(C=C)=O)n2)CCC1 Chemical compound CN1[C@H](COc2nc(CN(CC3)c4c(cccc5)c5ccc4)c3c(N(CC3)CCN3C(C=C)=O)n2)CCC1 XMYPBYHRAIBTEZ-QHCPKHFHSA-N 0.000 description 1
- DFGKZGMPZJULDC-DQEYMECFSA-N CN1[C@H](COc2nc(CN(CC3)c4cccc5cccc(Cl)c45)c3c(N(CC3)C[C@H](CC#N)N3C(C(OC)=C)=O)n2)CCC1 Chemical compound CN1[C@H](COc2nc(CN(CC3)c4cccc5cccc(Cl)c45)c3c(N(CC3)C[C@H](CC#N)N3C(C(OC)=C)=O)n2)CCC1 DFGKZGMPZJULDC-DQEYMECFSA-N 0.000 description 1
- OBKBMFMBHWUYHS-DQEYMECFSA-N CN1[C@H](COc2nc(CN(CC3)c4cccc5ccccc45)c3c(N(CC3)C[C@H](CC#N)N3C(C=C)=O)n2)CCC1 Chemical compound CN1[C@H](COc2nc(CN(CC3)c4cccc5ccccc45)c3c(N(CC3)C[C@H](CC#N)N3C(C=C)=O)n2)CCC1 OBKBMFMBHWUYHS-DQEYMECFSA-N 0.000 description 1
- WZPYXLTZCVTREL-YDBIPVDTSA-N CN1[C@H](COc2nc(N(CC3)CC(CC#N)N3C3OC3C=C)c(CCN(C3)c4ccccc4OC(F)(F)F)c3n2)CCC1 Chemical compound CN1[C@H](COc2nc(N(CC3)CC(CC#N)N3C3OC3C=C)c(CCN(C3)c4ccccc4OC(F)(F)F)c3n2)CCC1 WZPYXLTZCVTREL-YDBIPVDTSA-N 0.000 description 1
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)c(CCN(C3)c4cccc5c4c(Cl)ccc5)c3n2)CCC1 Chemical compound CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)c(CCN(C3)c4cccc5c4c(Cl)ccc5)c3n2)CCC1 PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 description 1
- LTVKHYYCQYQXDM-JTHBVZDNSA-N C[C@@H](CN(CC1)C(C=C)=O)N1c1nc(OC[C@@H]2N(C)CCC2)nc(C2)c1CCN2c1cc(O)cc2ccccc12 Chemical compound C[C@@H](CN(CC1)C(C=C)=O)N1c1nc(OC[C@@H]2N(C)CCC2)nc(C2)c1CCN2c1cc(O)cc2ccccc12 LTVKHYYCQYQXDM-JTHBVZDNSA-N 0.000 description 1
- LTVKHYYCQYQXDM-GMAHTHKFSA-N C[C@@H](CN(CC1)C(C=C)=O)N1c1nc(OC[C@H]2N(C)CCC2)nc(C2)c1CCN2c1cc(O)cc2ccccc12 Chemical compound C[C@@H](CN(CC1)C(C=C)=O)N1c1nc(OC[C@H]2N(C)CCC2)nc(C2)c1CCN2c1cc(O)cc2ccccc12 LTVKHYYCQYQXDM-GMAHTHKFSA-N 0.000 description 1
- LGWLXNOJQYLNDP-VWNXMTODSA-N C[C@H](CN(CC1)c2nc(OC[C@H]3N(C)CCC3)nc(C3)c2CCN3c2cccc3ccccc23)N1C(C=C)=O Chemical compound C[C@H](CN(CC1)c2nc(OC[C@H]3N(C)CCC3)nc(C3)c2CCN3c2cccc3ccccc23)N1C(C=C)=O LGWLXNOJQYLNDP-VWNXMTODSA-N 0.000 description 1
- ZQKKPIWKNOKJMG-NZHJDXKMSA-N Cc1c2c(N(CC3)Cc4c3c(N(CC3)C=C(CC#N)N3C(/C=C/CO)=O)nc(OC[C@@H]3N(C)CCC3)n4)cccc2ccc1 Chemical compound Cc1c2c(N(CC3)Cc4c3c(N(CC3)C=C(CC#N)N3C(/C=C/CO)=O)nc(OC[C@@H]3N(C)CCC3)n4)cccc2ccc1 ZQKKPIWKNOKJMG-NZHJDXKMSA-N 0.000 description 1
- PTKJWNJYHGWQSD-PFDXZPFDSA-N Cc1c2c(N(CC3)Cc4c3c(N(CC3)C[C@H](CC#N)N3C(/C=C/CN(C3)CC3F)=O)nc(OC[C@H]3N(C)CCC3)n4)cccc2ccc1 Chemical compound Cc1c2c(N(CC3)Cc4c3c(N(CC3)C[C@H](CC#N)N3C(/C=C/CN(C3)CC3F)=O)nc(OC[C@H]3N(C)CCC3)n4)cccc2ccc1 PTKJWNJYHGWQSD-PFDXZPFDSA-N 0.000 description 1
- GCIBCXNMHYTFJB-UHFFFAOYSA-N Cc1cc(O)cc(N(CC2)Cc3c2c(N(CC2)CCN2C(C=C)=O)nc(OCCCN2CCOCC2)n3)c1C Chemical compound Cc1cc(O)cc(N(CC2)Cc3c2c(N(CC2)CCN2C(C=C)=O)nc(OCCCN2CCOCC2)n3)c1C GCIBCXNMHYTFJB-UHFFFAOYSA-N 0.000 description 1
- YPUTZWWHKAMVGK-UHFFFAOYSA-N Cc1ccc2[nH]ncc2c1N1Cc2ncnc(N(CC3)CCN3C(C=C)=O)c2CC1 Chemical compound Cc1ccc2[nH]ncc2c1N1Cc2ncnc(N(CC3)CCN3C(C=C)=O)c2CC1 YPUTZWWHKAMVGK-UHFFFAOYSA-N 0.000 description 1
- BWZAAMUSWRMXGW-IZZNHLLZSA-N Cc1cccc2c1c(N1Cc3nc(OC[C@@H]4N(C)CCC4)nc(N(CC4)C[C@H](CC#N)N4C(C(F)=C)=O)c3CC1)ccc2 Chemical compound Cc1cccc2c1c(N1Cc3nc(OC[C@@H]4N(C)CCC4)nc(N(CC4)C[C@H](CC#N)N4C(C(F)=C)=O)c3CC1)ccc2 BWZAAMUSWRMXGW-IZZNHLLZSA-N 0.000 description 1
- NTXRHPWWLPFAAB-JUSIKRICSA-N Cc1cccc2cccc(N3Cc4nc(OC[C@H](C5)N(C)CC5(F)F)nc(N(CC5)C[C@H](CC#N)N5C(/C=C/CN(C5)CC5F)=O)c4CC3)c12 Chemical compound Cc1cccc2cccc(N3Cc4nc(OC[C@H](C5)N(C)CC5(F)F)nc(N(CC5)C[C@H](CC#N)N5C(/C=C/CN(C5)CC5F)=O)c4CC3)c12 NTXRHPWWLPFAAB-JUSIKRICSA-N 0.000 description 1
- OMDVESRMCYZTTR-UHFFFAOYSA-N OCC(CC1)N1C1CCOCC1 Chemical compound OCC(CC1)N1C1CCOCC1 OMDVESRMCYZTTR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025051088A JP2025098159A (ja) | 2018-12-05 | 2025-03-26 | 組み合わせ療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775628P | 2018-12-05 | 2018-12-05 | |
| US62/775,628 | 2018-12-05 | ||
| PCT/US2019/064707 WO2020118066A1 (en) | 2018-12-05 | 2019-12-05 | Combination therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051088A Division JP2025098159A (ja) | 2018-12-05 | 2025-03-26 | 組み合わせ療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509724A true JP2022509724A (ja) | 2022-01-24 |
| JP2022509724A5 JP2022509724A5 (cg-RX-API-DMAC7.html) | 2022-10-12 |
Family
ID=70973971
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513314A Pending JP2022509724A (ja) | 2018-12-05 | 2019-12-05 | 組み合わせ療法 |
| JP2025051088A Pending JP2025098159A (ja) | 2018-12-05 | 2025-03-26 | 組み合わせ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051088A Pending JP2025098159A (ja) | 2018-12-05 | 2025-03-26 | 組み合わせ療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12377101B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3890716A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022509724A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102983430B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113164418A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019392683B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3112129A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202190630A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL281348B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2021002804A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202102357RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020118066A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202102016B (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025509202A (ja) * | 2022-03-04 | 2025-04-11 | イーライ リリー アンド カンパニー | Kras g12c阻害剤及びshp2阻害剤を含む治療方法 |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| US12208099B2 (en) * | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3112043A1 (en) * | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CN113382774A (zh) * | 2019-02-12 | 2021-09-10 | 诺华股份有限公司 | 包含tno155和krasg12c抑制剂的药物组合 |
| US20210040089A1 (en) * | 2019-08-07 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| BR112022006394A2 (pt) | 2019-10-02 | 2022-07-26 | Tolremo Therapeutics Ag | Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer |
| CN112694475B (zh) | 2019-10-23 | 2025-09-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| CN112778301A (zh) * | 2019-11-07 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | 四氢吡啶并嘧啶类抑制剂及其制备方法和应用 |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| TW202144349A (zh) * | 2020-04-30 | 2021-12-01 | 大陸商上海科州藥物研發有限公司 | 作為kras抑制劑的雜環化合物的製備及其應用方法 |
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| WO2021260110A1 (en) | 2020-06-25 | 2021-12-30 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
| AU2021298154A1 (en) * | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022066805A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| US20250195533A1 (en) * | 2020-12-11 | 2025-06-19 | Erasca, Inc. | Combination therapies for the treatment of cancer |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20240082218A1 (en) * | 2020-12-22 | 2024-03-14 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers |
| WO2022133731A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers |
| US20250177399A1 (en) * | 2021-01-29 | 2025-06-05 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3212085C (en) | 2021-04-07 | 2025-02-11 | Tolremo Therapeutics Ag | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER |
| US20240300980A1 (en) * | 2021-05-22 | 2024-09-12 | Shanghai Kechow Pharma, Inc. | Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment |
| TW202317100A (zh) * | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
| CN115521312A (zh) * | 2021-06-24 | 2022-12-27 | 上海希迈医药科技有限公司 | Adagrasib的固体形式及其制备方法 |
| KR20240114793A (ko) | 2021-11-05 | 2024-07-24 | 프론티어 메디슨즈 코포레이션 | Kras g12c 억제제 |
| AU2023356610A1 (en) * | 2022-10-05 | 2025-04-03 | Amgen Inc. | Tethered heterocyclic inhibitors of kras g12c mutant proteins and uses thereof |
| CN120693161A (zh) * | 2022-10-12 | 2025-09-23 | 锐新医药公司 | 用于治疗癌症的包含第一ras抑制剂、第二ras抑制剂以及shp2抑制剂的组合物 |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025242126A1 (zh) * | 2024-05-22 | 2025-11-27 | 上海正大天晴医药科技开发有限公司 | 一种药物组合及其应用 |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017201161A1 (en) * | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
Family Cites Families (226)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613785B2 (en) | 1998-07-21 | 2003-09-02 | Smithkline Beecham Plc | Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| CA2432578C (en) | 2001-01-02 | 2008-04-01 | F. Hoffmann-La Roche Ag | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
| US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US20040043434A1 (en) | 2002-06-13 | 2004-03-04 | Gen-Sheng Feng | Shp-2 tyrosine phosphatase and embryonic stem cell differentiation |
| WO2004041216A2 (en) | 2002-11-05 | 2004-05-21 | Mount Sinai School Of Medicine Of New York University ; | Ptpn11 (shp-2) mutations and cancer |
| WO2005094314A2 (en) | 2004-03-26 | 2005-10-13 | The Burnham Institute | Modulators of shp2 tyrosine phosphatase and their use in the treatment of body weight disorders |
| EP1728790A1 (en) | 2005-06-01 | 2006-12-06 | Max-Delbrück-Centrum Für Molekulare Medizin | Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases |
| US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| US7547760B2 (en) | 2006-07-03 | 2009-06-16 | West Virginia University | Peptides and chemical compound for inhibition of SHP2 function |
| WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| US20100210649A1 (en) | 2006-12-21 | 2010-08-19 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| WO2008103470A2 (en) | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
| WO2009047255A1 (en) | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| US8163763B2 (en) | 2008-07-31 | 2012-04-24 | Genentech, Inc. | Pyrimidine compounds, compositions and methods of use |
| WO2010120996A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| US20130029978A1 (en) | 2009-12-25 | 2013-01-31 | Mochida Pharmaceutical Co., Ltd. | Novel aryl urea derivative |
| WO2011082285A1 (en) | 2009-12-30 | 2011-07-07 | Avila Therapeutics, Inc. | Ligand-directed covalent modification of protein |
| NL2008335A (en) | 2011-04-07 | 2012-10-09 | Asml Netherlands Bv | Lithographic apparatus, device manufacturing method, and method of correcting a mask. |
| WO2013155223A1 (en) | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| US9695133B2 (en) | 2012-07-13 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use |
| KR102373193B1 (ko) | 2012-11-21 | 2022-03-10 | 얀센 바이오테크 인코포레이티드 | 이중특이성 EGFR/c-Met 항체 |
| WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
| TW201524952A (zh) | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Kras g12c之共價抑制劑 |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
| MX380928B (es) | 2013-10-10 | 2025-03-12 | Araxes Pharma Llc | Inhibidores de kras g12c. |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| EP3148981A4 (en) | 2014-05-30 | 2017-11-08 | The Trustees of Columbia University in the City of New York | Multivalent ras binding compounds |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10017540B2 (en) | 2015-03-11 | 2018-07-10 | California Institute Of Technology | Cyclic peptide binder against oncogenic K-Ras |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| WO2016172692A1 (en) | 2015-04-24 | 2016-10-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Mutant kras inhibitors |
| AU2016258192B2 (en) | 2015-05-06 | 2021-07-29 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| WO2016196591A1 (en) | 2015-06-01 | 2016-12-08 | Indiana University Research & Technology Corporation | Protein tyrosine phosphatases or shp2 inhibitors and uses thereof |
| WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| US10256121B2 (en) | 2015-07-06 | 2019-04-09 | Tokyo Electron Limited | Heated stage with variable thermal emissivity method and apparatus |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| HK1251624A1 (zh) | 2015-09-24 | 2019-02-01 | Ionis Pharmaceuticals, Inc. | Kras表达的调节剂 |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| JP2018533939A (ja) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Rasの阻害剤をスクリーニングするための方法 |
| US10670605B2 (en) | 2015-10-22 | 2020-06-02 | The Scripps Research Institute | Cysteine reactive probes and uses thereof |
| WO2017080980A1 (en) | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer |
| WO2017079864A1 (en) | 2015-11-12 | 2017-05-18 | Hangzhou Yier Biotech Co., Ltd. | Treatment of cancers related to chronically active ras |
| KR102932353B1 (ko) | 2015-11-16 | 2026-02-27 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017100279A1 (en) | 2015-12-09 | 2017-06-15 | West Virginia University | Chemical compound for inhibition of shp2 function and for use as an anti-cancer agent |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US20170283445A1 (en) | 2016-04-05 | 2017-10-05 | University Of South Carolina | Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Kras g12c変異体タンパク質の阻害剤 |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| MX2019006299A (es) | 2016-11-30 | 2019-11-12 | Bantam Pharmaceutical Llc | Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas. |
| JP2020513403A (ja) | 2016-11-30 | 2020-05-14 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーBantam Pharmaceutical, Llc | 置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法 |
| CN110291084A (zh) | 2016-12-15 | 2019-09-27 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| US10344026B2 (en) | 2017-01-18 | 2019-07-09 | Nantbio, Inc. | Compositions and methods of targeting mutant K-ras |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| US20200385364A1 (en) | 2017-01-26 | 2020-12-10 | Araxes Pharma Llc | Fused n-heterocyclic compounds and methods of use thereof |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法 |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| US11358940B2 (en) | 2017-04-20 | 2022-06-14 | The Regents Of The University Of California | K-Ras modulators |
| US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| CA3082579A1 (en) | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| JP7058718B2 (ja) | 2018-07-31 | 2022-04-22 | 本田技研工業株式会社 | 電力予測システム、電力予測装置、電力予測方法、プログラム、及び記憶媒体 |
| CN109413550B (zh) | 2018-09-30 | 2021-03-09 | 华为技术有限公司 | 音频播放电路和终端 |
| JP2022508651A (ja) * | 2018-10-08 | 2022-01-19 | レヴォリューション・メディスンズ,インコーポレイテッド | 癌を処置するためのshp2阻害剤組成物および方法 |
| CN111193490B (zh) | 2018-11-14 | 2025-05-13 | 天津大学 | 散热结构、带散热结构的体声波谐振器、滤波器和电子设备 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2020163598A1 (en) | 2019-02-07 | 2020-08-13 | The Regents Of The University Of California | Immunophilin-dependent inhibitors and uses thereof |
| EP3924687A4 (en) | 2019-02-11 | 2022-11-02 | Mesomat Inc. | SENSING FIBERS FOR STRUCTURAL STRESS MONITORING |
| KR102747104B1 (ko) | 2019-02-18 | 2024-12-27 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
| GB2613715B (en) | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| GB201902392D0 (en) | 2019-02-21 | 2019-04-10 | Cambridge Entpr Ltd | Modular binding proteins |
| WO2020176693A2 (en) | 2019-02-26 | 2020-09-03 | Cell Response, Inc. | Methods for treating map3k8 positive cancers |
| WO2020177629A1 (zh) | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
| US12117170B2 (en) | 2019-03-05 | 2024-10-15 | Questor Technology Inc. | Gas incinerator system |
| ES3010507T3 (en) | 2019-03-05 | 2025-04-03 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| EP3941938A1 (en) | 2019-03-06 | 2022-01-26 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| WO2020198125A1 (en) | 2019-03-22 | 2020-10-01 | Icahn School Of Medicine At Mount Sinai | Methods for treating colorectal cancer |
| WO2020205473A1 (en) | 2019-03-29 | 2020-10-08 | Decerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of kras associated diseases or disorders |
| WO2020205486A1 (en) | 2019-03-29 | 2020-10-08 | Kura Oncology, Inc. | Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors |
| KR102222693B1 (ko) | 2019-04-04 | 2021-03-04 | 금정제약 주식회사 | H-rev107 유래 펩타이드의 신규한 용도 |
| WO2020214537A1 (en) | 2019-04-15 | 2020-10-22 | Tosk, Inc. | Modulators of ras gtpase |
| US20200335182A1 (en) | 2019-04-16 | 2020-10-22 | Uratim Ltd. | Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions |
| EP3964516A4 (en) | 2019-04-28 | 2023-01-11 | Genfleet Therapeutics (Shanghai) Inc. | OXAAZACHUINAZOLINE-7( 8H)-KETONE COMPOUND, PROCESS FOR ITS PRODUCTION AND ITS PHARMACEUTICAL APPLICATION |
| HRP20231310T1 (hr) | 2019-05-10 | 2024-02-02 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| HUE065486T2 (hu) | 2019-05-10 | 2024-05-28 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| MY208668A (en) | 2019-05-14 | 2025-05-23 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| CA3141604A1 (en) | 2019-05-20 | 2020-11-26 | 1200 Pharma Llc | Kras g12c inhibitors and uses thereof |
| WO2020234103A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
| US12252486B2 (en) | 2019-05-21 | 2025-03-18 | Amgen Inc. | Solid state forms |
| BR112021023136A2 (pt) | 2019-05-21 | 2022-01-04 | Inventisbio Co Ltd | Compostos heterocíclicos, métodos de preparação e usos dos mesmos |
| CA3142404A1 (en) | 2019-06-07 | 2020-12-10 | Emory University | Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto |
| US20220304984A1 (en) | 2019-06-12 | 2022-09-29 | Vanderbilt University | Amino acid transport inhibitors and the uses thereof |
| WO2020252336A1 (en) | 2019-06-12 | 2020-12-17 | Vanderbilt University | Dibenzylamines as amino acid transport inhibitors |
| WO2021000885A1 (zh) | 2019-07-01 | 2021-01-07 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
| IL290276B2 (en) | 2019-08-02 | 2026-05-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Tetracyclic compounds, method for their preparation and use |
| US20210040089A1 (en) | 2019-08-07 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| CN114174298B (zh) | 2019-08-14 | 2023-08-01 | 正大天晴药业集团南京顺欣制药有限公司 | 哒嗪酮并嘧啶类衍生物及其医药用途 |
| CN112390797A (zh) | 2019-08-15 | 2021-02-23 | 微境生物医药科技(上海)有限公司 | 新型螺环类K-Ras G12C抑制剂 |
| CN114222743A (zh) | 2019-08-16 | 2022-03-22 | 劲方医药科技(上海)有限公司 | 氧代六元环并嘧啶类化合物,其制法与医药上的用途 |
| CN119454706A (zh) | 2019-08-22 | 2025-02-18 | 密歇根大学董事会 | 治疗kras相关癌症的方法 |
| CN114269735B (zh) | 2019-08-26 | 2024-02-23 | 南京创济生物医药有限公司 | 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用 |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| JP2022554042A (ja) | 2019-09-06 | 2022-12-28 | ウェルマーカー・バイオ・カンパニー・リミテッド | バイオマーカー型治療用組成物 |
| CN114616232B (zh) | 2019-09-06 | 2026-05-05 | 正大天晴药业集团南京顺欣制药有限公司 | 氮杂环庚烷并嘧啶类衍生物及其医药用途 |
| US20220331401A1 (en) | 2019-09-10 | 2022-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating kras mutant cancers |
| TW202124374A (zh) | 2019-09-13 | 2021-07-01 | 美商拜歐斯瑞克斯公司 | Ras蛋白降解劑、其醫藥組合物及其治療應用 |
| US20220402916A1 (en) | 2019-09-18 | 2022-12-22 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| CN116947885B (zh) | 2019-09-20 | 2026-01-23 | 上海济煜医药科技股份有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| CN114502165A (zh) | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| US20210094919A1 (en) | 2019-09-25 | 2021-04-01 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| CN114929706A (zh) | 2019-09-29 | 2022-08-19 | 百济神州有限公司 | Kras g12c的抑制剂 |
| CN112574224A (zh) | 2019-09-30 | 2021-03-30 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
| US20230257374A1 (en) | 2019-10-10 | 2023-08-17 | Innovent Biologics (Suzhou) Co., Ltd. | Novel kras g12c protein inhibitor, preparation method therefor, and use thereof |
| US20240139193A1 (en) | 2019-10-15 | 2024-05-02 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| JP6754125B1 (ja) | 2019-10-15 | 2020-09-09 | 学校法人東京理科大学 | Brap2作用増強剤 |
| CN112694475B (zh) | 2019-10-23 | 2025-09-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
| WO2021080359A1 (ko) | 2019-10-23 | 2021-04-29 | 에스케이바이오팜 주식회사 | 바이사이클릭 화합물 및 이의 용도 |
| AU2020369569B2 (en) | 2019-10-24 | 2026-06-18 | Amgen Inc. | Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| BR112022008375A2 (pt) | 2019-10-30 | 2022-07-12 | Genfleet Therapeutics Shanghai Inc | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste |
| WO2021084765A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd | 4-aminobut-2-enamide derivatives and salts thereof |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN113286794B (zh) | 2019-11-04 | 2024-03-12 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
| CN121471132A (zh) | 2019-11-04 | 2026-02-06 | 锐新医药公司 | Ras抑制剂 |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN112778301A (zh) | 2019-11-07 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | 四氢吡啶并嘧啶类抑制剂及其制备方法和应用 |
| EP4043478A4 (en) | 2019-11-07 | 2024-01-03 | Chugai Seiyaku Kabushiki Kaisha | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION |
| WO2021093758A1 (zh) | 2019-11-15 | 2021-05-20 | 四川海思科制药有限公司 | 一种嘧啶并环衍生物及其在医药上的应用 |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021104431A1 (zh) | 2019-11-29 | 2021-06-03 | 苏州信诺维医药科技股份有限公司 | Kras g12c抑制剂化合物及其用途 |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4015520B1 (en) | 2019-12-02 | 2025-02-19 | 280 Bio, Inc. | Oxygen-containing heterocyclic compound, preparation method and application thereof |
| WO2021113595A1 (en) | 2019-12-06 | 2021-06-10 | Beta Pharma, Inc. | Phosphorus derivatives as kras inhibitors |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| WO2021126799A1 (en) | 2019-12-18 | 2021-06-24 | Merck Sharp & Dohme Corp. | Macrocyclic peptides as potent inhibitors of k-ras g12d mutant |
| CA3165238A1 (en) | 2019-12-19 | 2021-06-24 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| WO2021121397A1 (zh) | 2019-12-19 | 2021-06-24 | 首药控股(北京)股份有限公司 | 取代的炔基杂环化合物 |
| CN114761408B (zh) | 2019-12-19 | 2023-09-15 | 贝达药业股份有限公司 | Kras g12c抑制剂及其在医药上的应用 |
| CA3164995A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| TR201920922A2 (tr) | 2019-12-20 | 2020-06-22 | Ankara Ueniversitesi | 3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler |
| CN113045565A (zh) | 2019-12-27 | 2021-06-29 | 微境生物医药科技(上海)有限公司 | 新型K-Ras G12C抑制剂 |
| AU2020414943A1 (en) | 2019-12-27 | 2022-08-04 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Spiro ring-containing quinazoline compound |
| WO2021139678A1 (zh) | 2020-01-07 | 2021-07-15 | 广州百霆医药科技有限公司 | 吡啶并嘧啶类kras g12c突变蛋白抑制剂 |
| WO2021139748A1 (en) | 2020-01-08 | 2021-07-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Spirocyclic tetrahydroquinazolines |
| WO2021142252A1 (en) | 2020-01-10 | 2021-07-15 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| EP4092026A4 (en) | 2020-01-13 | 2024-03-06 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | ARYL OR HETEROARYL PYRIDONE OR PYRIMIDINE DERIVATIVES, PRODUCTION METHOD AND USE THEREOF |
| KR102396930B1 (ko) | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| KR102382613B1 (ko) | 2020-01-15 | 2022-04-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| WO2021147967A1 (zh) | 2020-01-21 | 2021-07-29 | 南京明德新药研发有限公司 | 作为kras抑制剂的大环类化合物 |
| GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| US20230099858A1 (en) | 2020-02-20 | 2023-03-30 | Beta Pharma, Inc. | Pyridopyrimidine derivatives as kras inhibitors |
| TW202140450A (zh) | 2020-02-24 | 2021-11-01 | 大陸商泰勵生物科技(上海)有限公司 | 用於癌症治療的kras抑制劑 |
| EP4112606A4 (en) | 2020-02-24 | 2024-04-10 | Shanghai Zheye Biotechnology Co., Ltd. | Aromatic compound and use thereof in preparing antineoplastic drugs |
| WO2021173923A1 (en) | 2020-02-28 | 2021-09-02 | Erasca, Inc. | Pyrrolidine-fused heterocycles |
| CN114901663B (zh) | 2020-03-02 | 2024-07-02 | 上海喆邺生物科技有限公司 | 一类芳香杂环类化合物及其在药物中的应用 |
| US20230099204A1 (en) | 2020-03-03 | 2023-03-30 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present |
| CN115397413A (zh) | 2020-03-05 | 2022-11-25 | 密歇根大学董事会 | Egfr、kras、braf和其他靶标的抑制剂及其用途 |
| IL296091A (en) | 2020-03-05 | 2022-11-01 | Univ Michigan Regents | Inhibitors of braf, kras, egfr and other targets and their uses |
| CN115298174B (zh) | 2020-03-12 | 2023-11-03 | 德昇济医药(无锡)有限公司 | 嘧啶并杂环类化合物及其应用 |
| TW202144345A (zh) | 2020-03-17 | 2021-12-01 | 大陸商北京加科思新藥研發有限公司 | Kras突變蛋白抑制劑 |
| US12391692B2 (en) | 2020-03-25 | 2025-08-19 | Wigen Boimedicine Technology (Shanghai) Co., Ltd. | Spiro ring-containing quinazoline compound |
| AU2021248363B2 (en) | 2020-04-03 | 2024-02-15 | Medshine Discovery Inc. | Octahydropyrazinodiazanaphthyridine dione compounds |
| US20220370416A1 (en) | 2020-04-06 | 2022-11-24 | Arvinas Operations, Inc. | Compounds and methods for targeted degradation of kras |
| WO2021203768A1 (zh) | 2020-04-08 | 2021-10-14 | 江苏恒瑞医药股份有限公司 | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 |
| CN121270550A (zh) | 2020-04-16 | 2026-01-06 | 因赛特公司 | 稠合三环kras抑制剂 |
| WO2021216770A1 (en) | 2020-04-22 | 2021-10-28 | Accutar Biotechnology Inc. | Substituted tetrahydroquinazoline compounds as kras inhibitors |
| US20230242586A1 (en) | 2020-04-23 | 2023-08-03 | The Regents Of The University Of California | Ras inhibitors and uses thereof |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| CN115151532B (zh) | 2020-04-29 | 2023-06-06 | 北京泰德制药股份有限公司 | 喹喔啉二酮衍生物作为kras g12c突变蛋白的不可逆抑制剂 |
| EP4144732A4 (en) | 2020-04-29 | 2024-05-01 | Shanghai Ringene BioPharma Co., Ltd. | BENZOTHIAZOLYL BIARYL COMPOUND, PREPARATION METHOD AND USE THEREOF |
| TW202144349A (zh) | 2020-04-30 | 2021-12-01 | 大陸商上海科州藥物研發有限公司 | 作為kras抑制劑的雜環化合物的製備及其應用方法 |
| WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
| CN113666923A (zh) | 2020-05-15 | 2021-11-19 | 苏州泽璟生物制药股份有限公司 | 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用 |
| WO2021236475A1 (en) | 2020-05-18 | 2021-11-25 | Asinex Corporation | Compounds that inhibit asparagine synthetase and their methods of use |
| TWI799871B (zh) | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物,其製法與醫藥上的用途 |
| CA3180314A1 (en) | 2020-05-29 | 2021-12-02 | John Graeme HODGSON | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 |
| CN116034106B (zh) | 2020-06-02 | 2025-11-04 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
| WO2021245499A1 (en) | 2020-06-04 | 2021-12-09 | Pillai Universal Llc | Novel small molecules for targeted degradation of untargetable kras in cancer therapy |
| KR20230019855A (ko) | 2020-06-04 | 2023-02-09 | 안텐진 디스커버리 리미티드 | Kras g12c 단백질의 억제제 및 그의 용도 |
| WO2021248082A1 (en) | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021248090A1 (en) | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021248079A1 (en) | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021248083A1 (en) | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| US20230026856A1 (en) | 2020-06-05 | 2023-01-26 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021252339A1 (en) | 2020-06-08 | 2021-12-16 | Accutar Biotechnology, Inc. | Substituted purine-2,6-dione compounds as kras inhibitors |
| WO2021249563A1 (zh) | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| US20230227466A1 (en) | 2020-06-18 | 2023-07-20 | Shy Therapeutics, Llc | Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2021259331A1 (zh) | 2020-06-24 | 2021-12-30 | 南京明德新药研发有限公司 | 八元含n杂环类化合物 |
| WO2022002102A1 (en) | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| EP4182313A4 (en) | 2020-07-16 | 2024-10-09 | Mirati Therapeutics, Inc. | KRAS-G12D INHIBITORS |
| WO2022017339A1 (zh) | 2020-07-20 | 2022-01-27 | 江苏恒瑞医药股份有限公司 | 稠合哒嗪类衍生物、其制备方法及其在医药上的应用 |
| WO2022028346A1 (zh) | 2020-08-02 | 2022-02-10 | 上海喆邺生物科技有限公司 | 一种芳香类化合物及其在抗肿瘤药物中的应用 |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| WO2022028492A1 (en) | 2020-08-05 | 2022-02-10 | Beigene, Ltd. | Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors |
| US20230303551A1 (en) | 2020-08-13 | 2023-09-28 | Albert Einstein College Of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
-
2019
- 2019-12-05 US US17/275,181 patent/US12377101B2/en active Active
- 2019-12-05 EA EA202190630A patent/EA202190630A1/ru unknown
- 2019-12-05 AU AU2019392683A patent/AU2019392683B2/en active Active
- 2019-12-05 SG SG11202102357RA patent/SG11202102357RA/en unknown
- 2019-12-05 EP EP19893444.0A patent/EP3890716A4/en active Pending
- 2019-12-05 CN CN201980077511.4A patent/CN113164418A/zh active Pending
- 2019-12-05 WO PCT/US2019/064707 patent/WO2020118066A1/en not_active Ceased
- 2019-12-05 KR KR1020217008639A patent/KR102983430B1/ko active Active
- 2019-12-05 MX MX2021002804A patent/MX2021002804A/es unknown
- 2019-12-05 CA CA3112129A patent/CA3112129A1/en active Pending
- 2019-12-05 IL IL281348A patent/IL281348B2/en unknown
- 2019-12-05 JP JP2021513314A patent/JP2022509724A/ja active Pending
-
2021
- 2021-03-09 MX MX2024009727A patent/MX2024009727A/es unknown
- 2021-03-25 ZA ZA2021/02016A patent/ZA202102016B/en unknown
-
2025
- 2025-03-26 JP JP2025051088A patent/JP2025098159A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017201161A1 (en) * | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| ACS MEDICINAL CHEMISTRY LETTERS, vol. 9, JPN6023041451, 2018, pages 1230 - 1234, ISSN: 0005468491 * |
| NATURE CELL BIOLOGY, vol. 20, JPN6023041452, September 2018 (2018-09-01), pages 1064 - 1073, ISSN: 0005468492 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025509202A (ja) * | 2022-03-04 | 2025-04-11 | イーライ リリー アンド カンパニー | Kras g12c阻害剤及びshp2阻害剤を含む治療方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3890716A1 (en) | 2021-10-13 |
| US12377101B2 (en) | 2025-08-05 |
| IL281348B2 (en) | 2026-05-01 |
| US20220079947A1 (en) | 2022-03-17 |
| SG11202102357RA (en) | 2021-04-29 |
| WO2020118066A1 (en) | 2020-06-11 |
| MX2024009727A (es) | 2024-08-19 |
| AU2019392683B2 (en) | 2025-08-14 |
| CA3112129A1 (en) | 2020-06-11 |
| MX2021002804A (es) | 2021-07-15 |
| JP2025098159A (ja) | 2025-07-01 |
| ZA202102016B (en) | 2022-06-29 |
| KR20210113587A (ko) | 2021-09-16 |
| IL281348B1 (en) | 2026-01-01 |
| AU2019392683A1 (en) | 2021-04-01 |
| IL281348A (en) | 2021-04-29 |
| KR102983430B1 (ko) | 2026-06-26 |
| EA202190630A1 (ru) | 2021-10-11 |
| CN113164418A (zh) | 2021-07-23 |
| EP3890716A4 (en) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019392683B2 (en) | Combination therapies | |
| JP2022500381A (ja) | 組み合わせ療法 | |
| JP2022500384A (ja) | 組み合わせ療法 | |
| JP2022500385A (ja) | 組み合わせ療法 | |
| JP2022500388A (ja) | 組み合わせ療法 | |
| JP2024537140A (ja) | Kras g12d阻害剤とsos1阻害剤との併用療法 | |
| JP2024540839A (ja) | Kras g12d阻害剤とshp-2阻害剤との併用療法 | |
| JP2022500379A (ja) | 組み合わせ療法 | |
| JP2024521788A (ja) | 併用療法 | |
| US20250177399A1 (en) | Combination therapies | |
| HK40109896A (en) | Combination therapies of kras g12d inhibitors with shp-2 inhibitors | |
| EA044829B1 (ru) | Способы комбинированной терапии | |
| HK40109895A (en) | Combination therapies of kras g12d inhibitors with sos1 inhibitors | |
| EP4593964A2 (en) | Combination therapies | |
| HK40059386A (zh) | 组合疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221003 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221003 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231010 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240410 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240611 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240910 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20241126 |